Legend Biotech(DE:9LB)
€18.50-2.90 (-11.90%)
DE:9LB
Legend Biotech ownership
€18.50
At close:-2.90 (-11.90%)
Legend Biotech (9LB) Ownership - Who Owns Legend Biotech?
1 Followers
Legend Biotech (9LB) Ownership Overview
- 0.93% Insiders
- 14.55% Mutual Funds
- 2.32% Other Institutional Investors
- 3.52% ETFs
- 78.68% Public Companies and Individual Investors
The ownership structure of Legend Biotech (DE:9LB) stock is a mix of institutional, retail, and individual investors. Approximately 20.39% of the company’s stock is owned by Institutional Investors, 0.93% is owned by Insiders, and 78.68% is owned by Public Companies and Individual Investors.
The ownership structure of Legend Biotech (DE:9LB) stock is a mix of institutional, retail, and individual investors. Approximately 20.39% of the company’s stock is owned by Institutional Investors, 0.93% is owned by Insiders, and 78.68% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 30, 2026 | Corazon (corsee) D. Sanders | $258,920 | |
| Sep 22, 2026 | Carlos E Santos | $49,630 | |
| Jul 01, 2026 | Casey Patrick John | $88,800 | |
| Jun 28, 2026 | Ying Huang | $82,265 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Deerfield Management Company, Lp | €128,961,680 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| James E. Flynn | 8,137,638 | Institution | 4.18% | 167,049,433 |
| Fidelity Select Portfolios | 5,054,910 | Institution | 2.60% | 103,767,192 |
| BlackRock, Inc. | 4,726,534 | Institution | 2.43% | 97,026,290 |
| Fidelity Securities Fund | 4,694,010 | Institution | 2.41% | 96,358,637 |
| Ishares | 3,913,666 | Institution | 2.01% | 80,339,736 |
| Fidelity Rutland Square Trust Ii | 3,396,184 | Institution | 1.75% | 69,716,865 |
| Fidelity Investment Trust | 2,964,540 | Institution | 1.52% | 60,856,077 |
| Harbor Funds | 1,355,821 | Institution | 0.70% | 27,832,293 |
| Smallcap World Fund Inc | 1,321,196 | Institution | 0.68% | 27,121,511 |
| Fidelity Concord Street Trust | 1,242,536 | Institution | 0.64% | 25,506,779 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Fidelity Select Portfolios | 5,054,910 | Institution | 2.60% | 103,767,192 |
| Fidelity Securities Fund | 4,694,010 | Institution | 2.41% | 96,358,637 |
| Fidelity Rutland Square Trust Ii | 3,396,184 | Institution | 1.75% | 69,716,865 |
| Fidelity Investment Trust | 2,964,540 | Institution | 1.52% | 60,856,077 |
| Harbor Funds | 1,355,821 | Institution | 0.70% | 27,832,293 |
| Smallcap World Fund Inc | 1,321,196 | Institution | 0.68% | 27,121,511 |
| Fidelity Concord Street Trust | 1,242,536 | Institution | 0.64% | 25,506,779 |
| Fidelity Advisor Series I | 1,185,272 | Institution | 0.61% | 24,331,264 |
| Fidelity Contrafund | 1,043,388 | Institution | 0.54% | 21,418,669 |
| Fidelity Advisor Series Vii | 1,019,556 | Institution | 0.52% | 20,929,446 |
FAQ
Who Owns Legend Biotech (DE:9LB)?
According to the latest TipRanks data, approximately 20.39% of the company's stock is held by institutional investors, 0.93% is held by insiders, and 78.68% is held by public companies and individual investors.
What percentage of Legend Biotech (DE:9LB) stock is held by institutional investors?
According to the latest TipRanks data, approximately 20.39% of Legend Biotech (DE:9LB) stock is held by institutional investors: 14.55% by mutual funds, 3.52% by ETFs and 2.32% by other institutional investors.
What percentage of Legend Biotech (DE:9LB) stock is held by retail investors?
According to the latest TipRanks data, approximately 78.68% of Legend Biotech (DE:9LB) stock is held by public companies and individual investors.
Who owns the most shares of Legend Biotech (DE:9LB)?
James E. Flynn owns the most shares of Legend Biotech (DE:9LB).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
